Heart health and visceral fat are closely linked in ways that standard weight measurements often fail to reveal. Unlike subcutaneous fat stored beneath the skin, visceral fat accumulates deep within the abdominal cavity, surrounding vital organs and releasing harmful substances directly into the bloodstream. This metabolically active fat drives inflammation, insulin resistance, and abnormal cholesterol levels — all of which place significant strain on the cardiovascular system. Crucially, visceral fat can be elevated even in people who appear slim. This article explains what visceral fat is, how to recognise it, what NHS guidance recommends, and how to reduce your risk.

What Is Visceral Fat and How Does It Differ From Other Body Fat?

Visceral fat accumulates deep within the abdominal cavity around vital organs and is far more metabolically harmful than subcutaneous fat, promoting insulin resistance, raised triglycerides, and systemic inflammation.

Body fat is not a single, uniform tissue. It exists in distinct compartments, each with different metabolic properties and health implications. The two principal types are subcutaneous fat — the layer stored just beneath the skin — and visceral fat, which accumulates deep within the abdominal cavity, surrounding vital organs such as the liver, pancreas, and intestines. It is this deeper fat depot that is strongly associated with higher cardiometabolic risk. It is worth noting that gluteofemoral subcutaneous fat (around the hips and thighs) appears to be metabolically neutral or even modestly protective, highlighting that not all body fat carries the same implications.

Visceral fat is metabolically active in ways that subcutaneous fat is not. It releases pro-inflammatory cytokines and free fatty acids directly into the portal circulation, which feeds the liver. This process can promote insulin resistance, raise triglyceride levels, lower HDL ('good') cholesterol, and increase systemic inflammation — all of which place significant strain on the heart and blood vessels.

Importantly, visceral fat is not always visible. A person may appear slim or carry a 'normal' body weight and yet harbour elevated levels of visceral adiposity — sometimes described colloquially as being 'TOFI' (Thin Outside, Fat Inside). This is an informal description rather than a clinical diagnosis, but it highlights why standard weight-based assessments such as BMI alone may fail to detect visceral fat accumulation. Understanding the distinction between fat types is therefore a critical first step in assessing cardiovascular risk accurately.

Further reading: NHS Live Well — waist size and health; British Heart Foundation — visceral fat and heart risk.

Recognising the Signs of Excess Visceral Fat

A waist circumference above NHS thresholds (≥94 cm in men, ≥80 cm in women) is the most accessible indicator of excess visceral fat, often accompanied by raised blood glucose, high triglycerides, or elevated blood pressure.

Because visceral fat lies deep within the abdomen, it does not always produce obvious outward signs. However, several indicators may suggest elevated visceral fat levels, particularly when considered together rather than in isolation.

Waist circumference is one of the most accessible and clinically useful proxy measures. According to NHS guidance, the following thresholds are associated with increased health risk, including cardiovascular disease and type 2 diabetes:

• Men: ≥94 cm (37 inches) — increased risk; ≥102 cm (40 inches) — high risk

• Women: ≥80 cm (31.5 inches) — increased risk

To measure accurately, place the tape measure at the midpoint between the lower rib and the top of the hip bone (iliac crest), and measure after a gentle exhalation, without pulling the tape tight.

For people of South Asian, Chinese, Japanese, and some other ethnic backgrounds, NICE guidance (PH46) supports using lower BMI thresholds to trigger assessment and intervention, reflecting differing patterns of fat distribution and metabolic risk. Where ethnic-specific waist cut-offs are used clinically (for example, ≥90 cm for South Asian men), these should be interpreted alongside broader risk assessment rather than in isolation.

Other features that may be associated with excess visceral fat include:

• A protruding or 'apple-shaped' abdomen, even in the absence of overall obesity

• Elevated blood glucose, non-diabetic hyperglycaemia (NDH) (HbA1c 42–47 mmol/mol), or a diagnosis of type 2 diabetes (HbA1c ≥48 mmol/mol)

• Raised blood pressure or a diagnosis of hypertension

• Abnormal lipid profiles, particularly high triglycerides and low HDL cholesterol

• Fatigue, poor sleep quality, or a diagnosis of obstructive sleep apnoea

These features are risk markers and associations — they are not diagnostic of visceral fat accumulation on their own, and many individuals may be entirely asymptomatic. Metabolic blood tests and clinical assessment by a healthcare professional are necessary to build a fuller picture. Recognising these potential indicators can, however, prompt earlier investigation and intervention.

Reference: NHS Live Well — how to measure your waist; NICE PH46 — BMI thresholds for Black, Asian and other minority ethnic groups.

NHS Guidance on Assessing and Monitoring Visceral Fat Levels

NHS and NICE guidance recommends waist circumference, waist-to-height ratio (ideally below 0.5), and the QRISK3 tool alongside lipid and HbA1c blood tests to assess visceral fat-related cardiovascular risk.

In clinical practice, visceral fat is not routinely measured directly. Gold-standard methods — such as MRI or CT scanning — are expensive, CT involves ionising radiation, and neither is practical for population-level screening. Instead, NHS and NICE guidance recommends a combination of accessible proxy measures to estimate cardiometabolic risk.

Waist circumference remains the most widely recommended bedside tool. NICE guidelines on obesity (CG189) support its use alongside BMI to better characterise risk, particularly in individuals with a BMI in the 'normal' or 'overweight' range. The waist-to-height ratio — ideally kept below 0.5 — is also endorsed by NICE as a useful screening tool, as it accounts for differences in body size.

For broader cardiovascular risk assessment, NICE (NG238) recommends the QRISK3 tool, which incorporates age, blood pressure, cholesterol levels, ethnicity, and the presence of conditions such as type 2 diabetes — many of which are directly influenced by visceral adiposity. Where QRISK3 indicates a 10-year cardiovascular risk of 10% or greater, NICE recommends offering a statin for primary prevention, following shared decision-making with the patient.

Blood tests used in assessment should include a non-fasting lipid profile and HbA1c (with fasting plasma glucose added where clinically indicated), in line with current UK practice. Patients aged 40–74 who are not already on a statin or known to have cardiovascular disease are eligible for an NHS Health Check in England, which includes blood pressure measurement, cholesterol testing, and a cardiovascular risk score calculation.

Monitoring frequency should be tailored to individual risk. As a general guide:

• Lower-risk individuals may have opportunistic checks at least every five years

• Those at elevated risk or on treatment should be reviewed more frequently, as agreed with their GP or healthcare team

Review should include blood pressure, non-fasting lipid profile, HbA1c, and repeat waist circumference measurements to track the impact of lifestyle changes and guide decisions about pharmacological intervention where appropriate.

References: NICE NG238 — cardiovascular disease risk assessment and lipid modification; NICE CG189 — obesity; NHS Health Check programme.

Lifestyle Changes to Reduce Visceral Fat and Protect Your Heart

Visceral fat responds well to lifestyle changes; UK guidelines recommend at least 150 minutes of moderate aerobic activity weekly, a diet low in ultra-processed foods, reduced alcohol intake, and improved sleep.

The encouraging news is that visceral fat is highly responsive to lifestyle modification — often more so than subcutaneous fat. Evidence consistently shows that targeted changes to diet, physical activity, sleep, and alcohol intake can meaningfully reduce visceral adiposity and, in turn, lower cardiovascular risk.

Dietary changes are foundational. A diet rich in whole grains, vegetables, legumes, lean proteins, and healthy fats (such as those found in oily fish, nuts, and olive oil) has been associated with reductions in visceral fat. Conversely, diets high in refined carbohydrates, added sugars, and ultra-processed foods promote visceral fat accumulation. Reducing alcohol intake is also important: UK Chief Medical Officers' low-risk drinking guidelines advise consuming no more than 14 units of alcohol per week, spread over three or more days, with several alcohol-free days each week.

Physical activity plays a particularly powerful role. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training can reduce visceral fat, even when overall weight change is modest. UK Chief Medical Officers' physical activity guidelines for adults recommend:

• At least 150 minutes of moderate-intensity aerobic activity per week, or 75 minutes of vigorous-intensity activity (or an equivalent combination)

• Muscle-strengthening activities on two or more days per week

• Minimising prolonged periods of sitting throughout the day

Sleep quality and stress management are often overlooked but clinically significant. Chronic sleep deprivation and persistently elevated cortisol — associated with ongoing psychological stress — are independently linked to visceral fat accumulation. Addressing these factors through good sleep hygiene, mindfulness, or psychological support can complement dietary and exercise interventions. The NHS provides patient-facing resources on sleep hygiene and stress management.

Small, sustainable changes tend to be more effective long-term than rapid, restrictive approaches. Even a 5–10% reduction in body weight has been shown to produce clinically meaningful reductions in visceral fat and associated cardiovascular risk markers.

References: UK Chief Medical Officers' Physical Activity Guidelines (Adults); UK Chief Medical Officers' Low Risk Drinking Guidelines; NHS — sleep and tiredness.

When to Seek Medical Advice About Visceral Fat and Heart Risk

Seek GP advice if your waist circumference exceeds recommended thresholds, you have raised blood pressure, cholesterol, or blood glucose, or you have not yet had an NHS Health Check (available to adults aged 40–74 in England).

Whilst lifestyle changes can be initiated independently, there are circumstances in which it is important to seek professional medical advice. Understanding when to act — and how urgently — can make a significant difference to long-term outcomes.

Call 999 immediately if you experience symptoms that may indicate a heart attack, including:

• Severe, sudden, or persistent chest pain or pressure

• Chest pain spreading to the arm, jaw, neck, or back

• Breathlessness, sweating, or nausea alongside chest discomfort

• Sudden collapse or loss of consciousness

Contact NHS 111 for urgent advice if you have concerning symptoms that are not immediately life-threatening.

Contact your GP if you:

• Have a waist circumference above the recommended thresholds and have not had a recent cardiovascular risk assessment

• Have been told you have high blood pressure, raised cholesterol, or elevated blood glucose — particularly in combination

• Have a strong family history of heart disease, stroke, or type 2 diabetes

• Are experiencing symptoms such as chest pain on exertion, breathlessness, palpitations, or unexplained fatigue that have not been investigated

• Have not yet had an NHS Health Check (available to adults aged 40–74 in England)

For individuals already diagnosed with conditions such as type 2 diabetes, hypertension, or metabolic-associated steatotic liver disease (MASLD, previously termed NAFLD), closer monitoring of visceral fat-related risk factors is particularly important. NICE guidelines support the use of pharmacological therapies where appropriate:

• Statins are recommended for primary prevention of cardiovascular disease when QRISK3 10-year risk is ≥10%, following shared decision-making (NICE NG238)

• Antihypertensives are initiated and titrated according to NICE NG136, which includes ambulatory or home blood pressure monitoring to confirm diagnosis

• GLP-1 receptor agonists (such as semaglutide or liraglutide) are used within specific NICE-approved criteria: in type 2 diabetes management (NICE NG28) or in specialist weight management services meeting defined eligibility criteria (NICE TA875 for semaglutide; NICE TA593 for liraglutide). They are not licensed or indicated solely for the treatment of visceral fat

• SGLT2 inhibitors are also recommended by NICE (NG28) for adults with type 2 diabetes and have demonstrated cardiovascular and renal benefits

• For MASLD/NAFLD, assessment and monitoring should follow NICE NG49

Risk is cumulative and context-dependent; no single sign or test is diagnostic in isolation. A healthcare professional can provide a holistic assessment, taking into account your individual history, ethnicity, lifestyle, and test results. Early intervention — before cardiovascular disease develops — remains the most effective strategy for protecting the heart in the context of visceral fat as a modifiable risk factor.

References: NHS — heart attack symptoms and when to call 999; NICE NG238 — CVD risk and lipid modification; NICE NG136 — hypertension; NICE NG28 — type 2 diabetes; NICE TA875 and TA593 — weight management; NICE NG49 — MASLD/NAFLD.

Frequently Asked Questions